Posts for Ticker ‘OPTR’

24/7 Day Trading Alerts (CROX)(OPTR)(FEED)(NTAP)(AMAG)

R218533_855025

Things are so bad at Crocs (CROX) that it is off nearly 50% down near $1.

Optimer Pharmaceuticals (OPTR) continues to be volatility. Details here..

AgFeed (FEED) is getting crushed.

NetApp (NTAP) is today’s tech winner.

AMAG Pharmaceuticals (AMAG) is making a big run up.

Posted on: November 13, 2008 – 9:33 am in Research, , , , ,

24/7 Wall St. Day Trading Alert (FMCN)(SGMO)(OPTR)(GS)(LVS)(WYNN)(MPEL)

Cammonopoly_wideweb__430x3250Focus Media (FMCN) is getting crushed this morning after posted bad numbers. Details..

Sangamo Biosciences (SGMO) ran into drug trial troubles and will trade way down.

Optimer Pharmaceuticals (OPTR) is ready for a big move up after good results from its new antibotic product.

Goldman Sachs (GS) is ready to sell off on concerns about earnings and the potential need to raise more cash.

The Las Vegas Sands (LVS) could lose it casino in Macau. The is causing moves in Wynn (WYNN) and Melco Crown  (MPEL).

Douglas A. McIntyre

Posted on: November 11, 2008 – 9:11 am in Research, , , , , ,

Top Pre-Market Analyst Upgrades (FRPT, INFY, NZ, OPTR, UTHR, USB, VMW)

Money_stack_picThese are the top analyst upgrades we are seeing from Wall Street early this Tuesday morning:

  • Force Protection (NASDAQ: FRPT) Raised to Buy at Collins Stewart.
  • Infosys (NASDAQ: INFY) Started as Outperform at William Blair.
  • Netezza (NYSE: NZ) Started as Outperform at Oppenheimer.
  • Optimer Pharmaceuticals (NASDAQ: OPTR) Raised to Outperform at Baird.
  • United Therapeutics (NASDAQ: UTHR) Started as Buy at Deutsche Bank.
  • US Bancorp (NYSE: USB) Raised to Hold from Sell at Sandler O’Neill.
  • VMware (NYSE: VMW) Started as Perform at Oppenheimer.

Jon C. Ogg
November 11, 2008

Posted on: November 11, 2008 – 7:42 am in Analyst Calls, , , , , , ,

Optimer Pharmaceuticals Files $100 Million Shelf (OPTR)

Optimer Pharmaceuticals, Inc. (NASDAQ" OPTR) has filed an open shelf registration last night with the SEC that will allow it to sell up to $100 million in any of the following types of securities:  Common Stock; Preferred Stock; Debt Securities; Warrants; Units.

The company is focused on discovering, developing and commercializing anti-infective products, and initial development efforts are to treat gastrointestinal infections and related diseases where current therapies have limitations.  The company currently has two late-stage anti-infective product candidates, OPT-80 and Prulifloxacin.

OPT-80 is the lead product candidate and is an antibiotic that is currently in two Phase III registration trials for the treatment of Clostridium difficile-infections, also known as Clostridium difficile-associated disease, the most common nosocomial diarrhea. Prulifloxacin is an antibiotic that is currently in two Phase III trials for the treatment of infectious diarrhea in travelers, a community-acquired infection often caused by a broad range of bacteria.  The company developing additional product candidates using its proprietary technology, including its OPopS drug discovery platform.

We frequently cover secondary offerings and other issues around IPO’s that include back door plays into IPO’s, spin-offs, restructurings, recapitalizations, and more in our open email distribution list.

Optimer shares are down 1.4% at $6.21 today, and its 52-week trading range is $5.90 to $10.42.  Its current market cap is $172.95 million.

Jon C. Ogg
March 28, 2008

Jon Ogg produces the Special Situation Investing Newsletter and he can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Posted on: March 28, 2008 – 1:57 pm in Biotech, Secondary Offering,